Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 110
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | ||
| NCT05592938 | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) | ||
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) | ||
| NCT06279260 | National Robotics-Assisted Radical Prostatectomy Database | ||
| NCT05263700 | FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary | ||
| NCT00581880 | Measuring Hope and Hopelessness in Cancer | ||
| NCT07138222 | IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma | ||
| NCT04534725 | COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; | ||
| NCT05560659 | Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy | ||
| NCT03161756 | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | ||
| NCT04801966 | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | ||
| NCT06812715 | Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib | ||
| NCT05024318 | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma | ||
| NCT03307759 | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma | ||
| NCT00753727 | Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma | ||
| NCT00110162 | Androgen Deprivation Therapy in Treating Patients With Prostate Cancer | ||
| NCT02662062 | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer | ||
| NCT04769817 | ProsTIC Registry of Men Treated With PSMA Theranostics | ||
| NCT03806764 | Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient | ||
| NCT02855203 | Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours | ||
| NCT05196789 | Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) | ||
| NCT03302728 | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma | ||
| NCT05154162 | PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI | ||
| NCT04619147 | Invasive Fungal Infections in Patients Following Stem Cell Transplant | ||
| NCT00377195 | Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma | ||
| NCT06631872 | Implementing Surgery School Prehabilitation Using Telehealth | ||
| NCT05169177 | Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy | ||
| NCT04985721 | A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects | ||
| NCT04074460 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study | ||
| NCT06480396 | High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma | ||
| NCT00482261 | A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression | ||
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) | ||
| NCT02468687 | NMP in Relapsed / Refractory Myeloma | ||
| NCT05063838 | Perioperative Pharmacogenomic Testing | ||
| NCT05666700 | CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study | ||
| NCT00418210 | Accelerated Partial Breast Irradiation for Early Breast Cancer | ||
| NCT05366153 | Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer | ||
| NCT00193934 | Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer | ||
| NCT07241715 | Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE) | ||
| NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | ||
| NCT00335348 | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | ||
| NCT04319783 | Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA | ||
| NCT05053854 | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | ||
| NCT06127654 | Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy | ||
| NCT02303366 | Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 | ||
| NCT06510699 | Pharmacogenomics for Better Treatment of Fungal Infections in Cancer | ||
| NCT06414148 | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma | ||
| NCT03851146 | A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours | ||
| NCT05864742 | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | ||
| NCT06882499 | Stereotactic Ablative Body Radiotherapy (SABR) with Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II |
